Ra Capital Management, L.P. Vaxcyte, Inc. Transaction History

Ra Capital Management, L.P.

$4.82 Billion
Q1 2025

A detailed history of Ra Capital Management, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 12,189,149 shares of PCVX stock, worth $453 Million. This represents 9.56% of its overall portfolio holdings.

Number of Shares

12,189,149

Previous 8,689,190 40.28%

Holding current value

$453 Million

Previous $711 Million 35.29%

% of portfolio

9.56%

Previous 11.52%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$37.76 - $92.13 $132 Million - $322 Million	3,499,959 Added 40.28%	12,189,149 $460 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $34.2 Million - $56.9 Million	485,436 Added 5.92%	8,689,190 $992 Million
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $493 Million - $646 Million	8,203,754 New	8,203,754 $619 Million
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $18.7 Million - $25.3 Million	312,500 Added 3.96%	8,203,754 $560 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $358 Million - $500 Million	7,891,254 New	7,891,254 $496 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $20.8 Million - $32.4 Million	600,000 Added 8.23%	7,891,254 $394 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $52 Million - $67.7 Million	1,433,795 Added 24.48%	7,291,254 $273 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $26.3 Million - $61.2 Million	1,276,256 Added 27.86%	5,857,459 $281 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $5.95 Million - $8.98 Million	340,739 Added 8.04%	4,581,203 $111 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $6.64 Million - $9.09 Million	343,599 Added 8.82%	4,240,464 $101 Million
Q3 2021 Nov 15, 2021	BUY	$20.26 - $26.97 $629,214 - $837,607	31,057 Added 0.8%	3,896,865 $98.9 Million
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $2.89 Million - $4.52 Million	155,109 Added 4.18%	3,865,808 $76.4 Million
Q4 2020 Feb 16, 2021	SELL	$26.57 - $51.74 $41.8 Million - $81.4 Million	-1,573,119 Reduced 29.77%	3,710,699 $98.6 Million
Q3 2020 Nov 16, 2020	SELL	$26.5 - $55.4 $5.44 Million - $11.4 Million	-205,363 Reduced 3.74%	5,283,818 $261 Million
Q2 2020 Aug 14, 2020	BUY	$26.15 - $35.45 $144 Million - $195 Million	5,489,181 New	5,489,181 $174 Million

Others Institutions Holding PCVX

# of Institutions

345

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.21B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.

Account

Ra Capital Management, L.P. Vaxcyte, Inc. Transaction History